Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Azenta, Inc.
AZTA
NASDAQ·Healthcare·Medical - Instruments & Supplies·Mkt cap $1.2B
$25.84
▼ -1.34%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$15.93 - $41.73
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 21.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Integrated end-to-end sample management solutions across products and services
- Proprietary automation and cold chain technology with high switching costs
- Established relationships with major pharmaceutical and biotech companies
- Global infrastructure and multi-geography operational capabilities
Bear Case
2 risks
- Average volatility.
- High premium - requires strong execution
Growth
Turning profitable
Increased pharmaceutical R&D spending and drug development pipeline expansion
Value
High premium - requires strong execution
Momentum
Strong
+14.2% over 3m
Quality
Strong
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying AZTA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 4, 2026
MAY 6, 2026
Reported EPS of -$0.04 vs $0.12 consensus (-132.6% surprise). Revenue of $144.8M vs $148.5M expected (-2.5%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-132.6%
Next: Aug 4, 2026
Revenue trend · last 8Q
—
—
—
—
+5%
-0%
+6%
+1%
Q2 24
Q3 24
Q4 24
Q1 24
Q2 25
Q3 25
Q4 25
Q1 25
$136.4M
$144.3M
$150.6M
$147.4M
$143.4M
$143.9M
$159.2M
$148.6M
Margins · last 8Q
Gross
42.9%
Operating
-3.3%
Profit
-10.4%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Needham · May 6, 2026